Sana Biotechnology, Inc 8-K, filed Jun 6, 2025
Sana Biotechnology, Inc. (SANA)
About this 8-K
Sana Biotechnology, Inc filed this 8-K on June 6, 2025, reporting on events of June 5, 2025.
Items reported
- Item 5.07: Shareholder vote results
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
|
|
|
|
|
|
|
|||
(State or other jurisdiction of incorporation) |
|
(Commission File Number)
|
|
(IRS Employer Identification Number) |
(Address of principal executive offices, including Zip Code)
Registrant’s telephone number, including area code:
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 5.07 Submission of Matters to a Vote of Security Holders.
Sana Biotechnology, Inc. (the “Company”) held its 2025 annual meeting of stockholders (the “Annual Meeting”) on June 5, 2025. The final results for each of the proposals submitted to a vote of the Company’s stockholders at the Annual Meeting are set forth below. These proposals are described in detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 25, 2025.
Proposal 1: The Company’s stockholders elected all the nominees to serve as Class I directors of the Company’s Board of Directors, each to serve for a three-year term expiring at the Company’s 2028 annual meeting of stockholders or until his or her respective successor is duly elected and qualified, by the votes set forth in the table below:
Nominees |
|
For |
|
Withheld |
|
Broker Non-Votes |
Steven D. Harr, M.D. |
|
147,857,094 |
|
11,540,847 |
|
20,921,414 |
Robert L. Rosiello |
|
158,192,667 |
|
1,205,274 |
|
20,921,414 |
Michelle Seitz, CFA |
|
147,879,439 |
|
11,518,502 |
|
20,921,414 |
Patrick Y. Yang, Ph.D. |
|
143,651,313 |
|
15,746,628 |
|
20,921,414 |
Proposal 2: The Company’s stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025, by the votes set forth in the table below:
For |
|
Against |
|
Abstain |
180,193,873 |
|
55,838 |
|
69,644 |
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
Sana Biotechnology, Inc. |
|
|
|
|
|
Date: June 6, 2025 |
|
By: |
/s/ Bernard J. Cassidy |
|
|
|
Bernard J. Cassidy |
|
|
|
Executive Vice President and General Counsel |
2